Previous 10 | Next 10 |
--In a Small Feasibility Study, UGN-102 Achieves a Complete Response in 75% (6 of 8) Patients --UGN-102 is Being Studied in Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commerciali...
UroGen Pharma ( NASDAQ: URGN ) is trading ~3% lower after Jefferies downgraded to hold from buy. Stock has risen ~22% in the last one year. Also Read - UroGen: Struggling With Revenue And With Cash Runway . For further details see: UroGen Pharma falls after...
Summary UroGen has an approved drug and a platform. However, there's not much growth in revenue. URGN's cash situation is not good, either. For further details see: UroGen: Struggling With Revenue And With Cash Runway
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights results from the first and largest post-commercial utilization review of JELMYTO ® (mitomycin) for pyelocaly...
--If approved, UGN-102 would be the first non-surgical primary therapeutic to treat a subset of bladder cancer characterized by high recurrence rates and multiple surgeries UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solution...
-- Results from this ongoing, noninterventional rollover study were presented at the 23 rd Annual Society of Urological Oncology (SUO) Meeting in San Diego UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat ...
--Results from this ongoing, non-interventional, rollover study were presented at the 23 rd Annual Society of Urologic Oncology (SUO) Meeting in San Diego UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to creating novel solutions that treat urothelial and specialty can...
- Fireside Chat November 29, 2022 from 3:55 – 4:15 PM ET - UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in a ...
-- 32-patient, multi-center study showed 9% occurrence of ureteral stenosis and 10% discontinuation rate -- All three stenosis patients were treated without later recurrence or chronic stenosis UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and co...
UroGen Pharma Ltd. (URGN) Q3 2022 Earnings Conference Call November 10, 2022 10:00 AM ET Company Participants Vincent Perrone - Senior Director-Investor Relations Liz Barrett - President & Chief Executive Officer Mark Schoenberg - Chief Medical Officer Je...
News, Short Squeeze, Breakout and More Instantly...
2024-06-25 07:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ord...
PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has commenced an underwritten public offering, subject to m...